Timothy D Clay

7PUBLICATIONS
25CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical ethicsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Feb 27, 2026
Clinical insights into the management of sleep disturbances within cancer care: a qualitative analysis.

Sam Adams, Timothy D Clay, Mitchell Turner

|Jul 01, 2020
Keeping Patients With Cancer Exercising in the Age of COVID-19.

Robert U Newton, Nicolas H Hart, Tim Clay

|May 03, 2020
Doctors' understanding of consent law.

Rohen Skiba, Nisha Sikotra, Alexandra Wilson

|Aug 13, 2019
Management of neutropenic fever in a private hospital oncology unit.

Rohen Skiba, Nisha Sikotra, Timothy Ball

|Sep 08, 2017
EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma.

Timothy D Clay, Prudence A Russell, Hongdo Do

Pageof 2